Skip to main content
main-content

25-02-2022 | ASCO GU 2022 | Conference coverage | Video

Neoadjuvant avelumab plus axitinib active in high-risk RCC

share
SHARE

Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps (4:20).

Related content

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.